Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer

Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Moufarrij, Sara, Srivastava, Aneil, Gomez, Stephanie, Hadley, Melissa, Palmer, Erica, Austin, Paul Tran, Chisholm, Sarah, Diab, Noor, Roche, Kyle, Yu, Angela, Li, Jing, Zhu, Wenge, Lopez-Acevedo, Micael, Villagra, Alejandro, Chiappinelli, Katherine B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044433/
https://ncbi.nlm.nih.gov/pubmed/32103105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-60409-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi